Opportunity Information: Apply for W81XWH 09 PCRP SIDA
Apply for W81XWH 09 PCRP SIDA
- The Dept. of the Army USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "FY09 DOD Prostate Cancer Synergistic Idea Development Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420 Military Medical Research and Development.
- This funding opportunity was created on May 5, 2009 and posted on Jan 24, 2009.
- Applicants must submit their applications by Jun 10, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $6,000,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 5 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The FY09 DOD Prostate Cancer Synergistic Idea Development Award (SIDA) is a funding opportunity under the Department of Defense Prostate Cancer Research Program (PCRP) aimed at speeding up meaningful progress in prostate cancer research by requiring true collaboration. The core idea is that some of the most important problems in prostate cancer cannot be solved efficiently by one lab working alone, even if that lab is strong. Instead, this mechanism is built for teams of two or three independent, faculty-level (or equivalent) principal investigators who bring different, complementary expertise to a single, jointly designed research project. The end goal is aligned with the PCRP vision of conquering prostate cancer by accelerating advances that could translate into better prevention, detection, diagnosis, or treatment strategies.
A defining feature of this award is how it treats collaboration and funding. The investigators must design one integrated project together, with clearly defined pieces that depend on each partner’s unique strengths. At the same time, each partner is formally recognized as a PI, submits a separate application, and receives an individual award tied to the shared project. Reviewers are explicitly looking for synergy, meaning the application needs to make a convincing case that the combined effort will produce more progress, faster, than the same investigators could achieve through parallel but separate projects. The expectation is that all PIs contribute meaningful intellectual leadership, with balanced effort unless there is a well-justified reason otherwise. The review also considers the investigators’ past collaborative experience, either with each other or in other team settings, as a signal that the partnership can function effectively.
The program places heavy emphasis on innovation and impact. Proposed work is expected to challenge existing assumptions, introduce new concepts, or attack a prostate cancer problem from a genuinely new angle. High-risk ideas are allowed, and even encouraged, as long as they are backed by a strong scientific rationale and have the potential for a significant payoff. Incremental projects that mainly extend already-published findings without a clear leap forward are specifically described as non-competitive for this mechanism. Impact is framed in practical terms: if the research succeeds, it should substantially advance methods or concepts relevant to human prostate cancer, including prevention, detection, diagnosis, or treatment.
The scope of research is broad, covering basic, preclinical, behavioral, and epidemiological studies, as long as the work is responsive to one or more of the FY09 PCRP focus areas (the specific focus areas are referenced in the full program announcement). One important boundary is that clinical trials are not permitted under this mechanism, and applicants are directed to guidance on how the program distinguishes clinical trials from other forms of clinical research. Also new for FY09, investigators who specifically want to conduct population-based studies are encouraged to consider a different PCRP mechanism, the Population Based Idea Development Award, rather than submitting those projects here.
Because collaboration is not treated as a casual add-on, applications must include concrete interaction plans. Teams need to spell out how they will communicate regularly, coordinate experiments and milestones, share results, and transfer data. Multi-institutional teams are allowed and are even encouraged when they strengthen the science, but they come with extra requirements: multi-institutional applications must include an intellectual property plan to address potential IP and materials issues up front and reduce institutional barriers that could get in the way of smooth cooperation and timely completion of the work.
Preliminary data are encouraged but not required. If preliminary data are included, they should come from the PI’s laboratory or from members of the collaborating team, and they should support the prostate cancer relevance and feasibility of the proposed approach. Even when proposing bold, unconventional ideas, the expectation is that the application is grounded in logical reasoning and a well-developed scientific argument based on the literature.
From an administrative standpoint, this opportunity (Funding Opportunity Number W81XWH-09-PCRP-SIDA) was posted January 24, 2009, with an application closing date of June 10, 2009, and an archive date of July 10, 2009. The funding instrument is listed as a cooperative agreement/grant within the Science and Technology and other Research and Development category. The Army (USAMRAA) is the sponsoring agency. The program anticipated about 5 awards, with estimated total funding of $6,000,000, under CFDA 12.420 (Military Medical Research and Development). Cost sharing was not required, and eligibility was described as unrestricted, subject to any additional eligibility language in the full announcement. For assistance, applicants were directed to CDMRP and program announcement help contacts for technical access and eReceipt support.
FY09 DOD Prostate Cancer Synergistic Idea Development Award (SIDA) - FAQs
1) What is the FY09 DOD Prostate Cancer Synergistic Idea Development Award (SIDA)?
The Synergistic Idea Development Award (SIDA) is a funding opportunity under the Department of Defense (DOD) Prostate Cancer Research Program (PCRP) designed to speed up meaningful progress in prostate cancer research by requiring true collaboration among investigators.
2) What is the main goal of the SIDA mechanism?
The main goal is to accelerate advances that could translate into improved prevention, detection, diagnosis, or treatment strategies for human prostate cancer, in alignment with the PCRP vision of conquering prostate cancer.
3) What makes this award different from typical single-lab research grants?
This mechanism is built around the idea that certain major prostate cancer problems cannot be solved efficiently by one lab alone. It requires an integrated, jointly designed project led by a small team with complementary expertise, rather than separate projects running in parallel.
4) How many investigators are required, and what level must they be?
Teams must consist of two or three independent, faculty-level (or equivalent) principal investigators (PIs) who bring different, complementary expertise to a single collaborative project.
5) Can the collaborating investigators be at different institutions?
Yes. Multi-institutional teams are allowed and even encouraged when they strengthen the science, but they come with additional requirements (such as an intellectual property plan).
6) What does "synergy" mean in the context of this award?
Synergy means reviewers expect a convincing case that the combined team effort will produce more progress, faster, than the same investigators could achieve through separate, parallel projects. The collaboration must be more than a simple division of labor.
7) Do all team members have to be listed as PIs?
Yes. Each partner is formally recognized as a PI and is expected to provide meaningful intellectual leadership to the shared project.
8) How is funding handled for collaborative teams under SIDA?
Although the project is jointly designed and integrated, each PI submits a separate application and receives an individual award tied to the shared collaborative project.
9) Is balanced effort across PIs required?
Reviewers expect balanced effort and meaningful intellectual contributions from all PIs, unless there is a well-justified reason for an imbalance.
10) Will reviewers consider the team’s prior experience working together?
Yes. Reviewers consider investigators’ past collaborative experience, either with each other or in other team settings, as an indicator that the partnership can function effectively.
11) What types of research are considered within scope?
The scope is broad and may include basic, preclinical, behavioral, and epidemiological studies, as long as the work is responsive to one or more of the FY09 PCRP focus areas referenced in the full program announcement.
12) Are clinical trials allowed under this award?
No. Clinical trials are not permitted under this mechanism. Applicants are directed to program guidance on how clinical trials are distinguished from other forms of clinical research.
13) Are population-based studies appropriate for SIDA?
For FY09, investigators specifically aiming to conduct population-based studies are encouraged to consider a different PCRP mechanism, the Population Based Idea Development Award, rather than submitting those projects under SIDA.
14) How important are innovation and impact in the review?
They are central. Proposed work is expected to challenge existing assumptions, introduce new concepts, or address a prostate cancer problem from a genuinely new angle, with the potential for significant payoff if successful.
15) Are high-risk ideas acceptable?
Yes. High-risk ideas are allowed and encouraged, provided they are supported by a strong scientific rationale and have the potential for substantial impact.
16) What types of projects are described as non-competitive?
Incremental projects that mainly extend already-published findings without a clear leap forward are specifically described as non-competitive for this mechanism.
17) What does the program mean by "impact"?
Impact is framed in practical terms: if successful, the research should substantially advance methods or concepts relevant to human prostate cancer, including prevention, detection, diagnosis, or treatment.
18) Are teams required to provide a collaboration or interaction plan?
Yes. Applications must include concrete interaction plans explaining how the team will communicate regularly, coordinate experiments and milestones, share results, and transfer data.
19) What additional requirement applies to multi-institutional applications?
Multi-institutional applications must include an intellectual property (IP) plan to address potential IP and materials issues up front and reduce institutional barriers to smooth cooperation and timely completion of the work.
20) Is preliminary data required?
No. Preliminary data are encouraged but not required.
21) If we include preliminary data, whose data should it be?
If included, preliminary data should come from the PI’s laboratory or from members of the collaborating team and should support prostate cancer relevance and feasibility.
22) How should teams justify bold or unconventional ideas without preliminary data?
Even for bold ideas, applications are expected to be grounded in logical reasoning and a well-developed scientific argument based on the literature.
23) What is the Funding Opportunity Number for this award?
The Funding Opportunity Number is W81XWH-09-PCRP-SIDA.
24) When was this opportunity posted and when did it close?
It was posted on January 24, 2009, with an application closing date of June 10, 2009. The archive date was July 10, 2009.
25) What agency sponsors this opportunity?
The sponsoring agency is the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA).
26) What is the funding instrument and category listed for this opportunity?
The funding instrument is listed as a cooperative agreement/grant, and the category is Science and Technology and other Research and Development.
27) How many awards and how much total funding were anticipated?
The program anticipated approximately 5 awards with estimated total funding of $6,000,000.
28) What CFDA number is associated with this opportunity?
The CFDA number listed is 12.420 (Military Medical Research and Development).
29) Is cost sharing required?
No. Cost sharing was not required for this opportunity.
30) Who is eligible to apply?
Eligibility was described as unrestricted, subject to any additional eligibility language in the full program announcement.
31) Where can applicants get help with the application process?
Applicants were directed to CDMRP and program announcement help contacts for technical access and eReceipt support.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: DoD Breast Cancer Impact Award
Previous opportunity: FY09 DOD Prostate Cancer Idea Development Award
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for W81XWH 09 PCRP SIDA
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (W81XWH 09 PCRP SIDA) also looked into and applied for these:
| Funding Opportunity |
|---|
| DoD Breast Cancer Impact Award Apply for W81XWH 09 BCRP IMPT Funding Number: W81XWH 09 BCRP IMPT Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Breast Cancer Multi Team Award Apply for W81XWH 09 BCRP MTA Funding Number: W81XWH 09 BCRP MTA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Network Science Collaborative Technology Alliance (NS CTA) Apply for W911NF 08 R 0013 Funding Number: W911NF 08 R 0013 Agency: Dept of the Army Materiel Command Category: Science and Technology and other Research and Development Funding Amount: $252,000,000 |
| Course, Curriculum, and Laboratory Improvement Apply for 09 529 Funding Number: 09 529 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $5,000,000 |
| DoD Peer Reviewed Medical Research Program Technology/Therapeutic Development Award Apply for W81XWH 09 PRMRP TTDA Funding Number: W81XWH 09 PRMRP TTDA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Medical Research Program Clinical Trial Award Apply for W81XWH 09 PRMRP CTA Funding Number: W81XWH 09 PRMRP CTA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Long Range Broad Agency Announcement (BAA) for Navy and Marine Corp Science and Technology Apply for ONRBAA09 001 Funding Number: ONRBAA09 001 Agency: Office of Naval Research Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Cooperative Ecosystem Studies Unit, Great Lakes Northern Forest CESU Apply for 09HQPA0019 Funding Number: 09HQPA0019 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| CBMS BAA 07 01 Apply for CBMS BAA 07 01 Funding Number: CBMS BAA 07 01 Agency: Dept. of the Army Space Missle Defense Comman Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Space Electronics Open 5 Year Broad Agency Announcement Apply for BAA VS 06 05 Funding Number: BAA VS 06 05 Agency: Air Force Research Lab Category: Science and Technology and other Research and Development Funding Amount: $150,000,000 |
| Space Components Technology Open 5 Year Broad Agency Announcement Apply for BAA VS 07 03 Funding Number: BAA VS 07 03 Agency: Air Force Research Lab Category: Science and Technology and other Research and Development Funding Amount: $48,000,000 |
| DoD Peer Reviewed Medical Research Program Investigator Initiated Research Award Apply for W81XWH 09 PRMRP IIRA Funding Number: W81XWH 09 PRMRP IIRA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Space Based Advanced Sensing and Protection Branch Open 5 Year Broad Agency Announcement Apply for BAA VS 07 07 Funding Number: BAA VS 07 07 Agency: Air Force Research Lab Category: Science and Technology and other Research and Development Funding Amount: $68,000,000 |
| DoD Autism Research Program Clinical Trial Award Apply for W81XWH 09 ARP CTA Funding Number: W81XWH 09 ARP CTA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Autism Research Program Idea Award Apply for W81XWH 09 ARP IDEA Funding Number: W81XWH 09 ARP IDEA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Robotics Collaborative Technology Alliance (CTA) Apply for W911NF 08 R 0012 Funding Number: W911NF 08 R 0012 Agency: Dept of the Army Materiel Command Category: Science and Technology and other Research and Development Funding Amount: $209,700,000 |
| Microsystems Technology Apply for DARPA BAA 08 18 PDF Funding Number: DARPA BAA 08 18 PDF Agency: DARPA Microsystems Technology Office Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Cognition and Neuroergonomics (CAN) Collaborative Technology Alliance (CTA) Apply for W911NF 08 R 0014 Funding Number: W911NF 08 R 0014 Agency: Dept of the Army Materiel Command Category: Science and Technology and other Research and Development Funding Amount: $130,000,000 |
| DoD Breast Cancer Idea Award Apply for W81XWH 09 BCRP IDEA Funding Number: W81XWH 09 BCRP IDEA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Breast Cancer Era of Scholar Award Apply for W81XWH 09 BCRP EOHS Funding Number: W81XWH 09 BCRP EOHS Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 09 PCRP SIDA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.